| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5537290 | Vaccine | 2017 | 10 Pages |
Abstract
Single-dose vaccination of SA4Ag and SA3Ag in healthy adults aged 65-85Â years safely induced rapid and robust functional immune responses, supporting further development of SA4Ag for the prevention of S. aureus disease in adults up to age 85Â years. Trial registration number: NCT01643941.
Keywords
DMCICSGCPSAECRM197SSIOPACLIALLOQFDAGMFRclfAGMTsTFnFunctional antibodiesStaphylococcus aureusS. aureusFBIinterferonIFNinterleukindiphtheria toxinlower limit of quantificationintracellular cytokine stainingFood and Drug Administrationadverse eventtumour necrosis factorsurgical site infectiongood clinical practiceSerious adverse eventconfidence intervalclumping factor AOpsonophagocytic activitygeometric mean titresVaccinepolymerase chain reactionPCRCapsular polysaccharideCapsular polysaccharidesData Monitoring Committee
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
C. Buddy Creech, Robert W. Jr, Eric A. Sheldon, David J. Seiden, Martin K. Kankam, Edward T. Zito, Douglas Girgenti, Joseph M. Severs, Frederick W. Immermann, Lisa K. McNeil, David Cooper, Kathrin U. Jansen, William Gruber, Joseph Eiden,